Form 4: Tenon Medical Director Awarded 20,293 RSUs

Tenon Medical, Inc. Director Kristine M. Jacques received a grant of 20,293 restricted stock units, which will vest in two equal tranches in 2026.

Summary

• Kristine M. Jacques, a Director of Tenon Medical, Inc. (TNON), was granted 20,293 Restricted Stock Units (RSUs).
• The transaction date for this acquisition was October 13, 2025.
• Each RSU represents a contingent right to receive one share of Tenon Medical common stock.
• The RSUs will vest in two equal installments: 50% on January 1, 2026, and the remaining 50% on July 31, 2026.
• Following this transaction, Kristine M. Jacques beneficially owns 20,293 derivative securities (RSUs) directly.

Sentiment

Score: 6

Explanation: The grant of Restricted Stock Units to a director is a standard practice that aligns the director's interests with long-term shareholder value, which is generally viewed positively.

Positives

• The grant of Restricted Stock Units to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• Equity compensation is a common practice to attract and retain qualified board members.

Negatives

• No immediate cash investment by the director, as RSUs are granted at a $0 price.

Future Outlook

The granted Restricted Stock Units are scheduled to vest in two tranches during 2026, converting into common stock of Tenon Medical, Inc.

Industry Context

The granting of Restricted Stock Units to directors is a standard practice in the medical device and broader public company sectors, serving as a key component of non-employee director compensation packages to align their interests with long-term shareholder value creation.

Comparison to Industry Standards

• Equity grants, particularly Restricted Stock Units, are a common form of compensation for non-executive directors across various industries, including medical technology.
• This practice is consistent with corporate governance best practices aimed at fostering long-term commitment and performance alignment. Specific comparable companies or projects are not detailed in this filing, but the general mechanism is standard.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the company's long-term performance, potentially benefiting shareholders through improved governance and strategic oversight.

Next Steps

• First tranche of 10,146.5 Restricted Stock Units will vest and convert into common stock on January 1, 2026.
• Second tranche of 10,146.5 Restricted Stock Units will vest and convert into common stock on July 31, 2026.

Key Dates

Keywords

Tenon Medical, TNON, Restricted Stock Units, RSU, Insider Transaction, Form 4, Equity Compensation, Director Compensation, Kristine M. Jacques